<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In patients at risk for <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e>, consideration is often given to placement of an inferior vena cava (IVC) filter to prevent propagation of a distal <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, long-term benefits remain controversial, and <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> and IVC <z:mp ids='MP_0005048'>thrombosis</z:mp> may result from the procedure itself </plain></SENT>
<SENT sid="2" pm="."><plain>Whether a filter if beneficial or even detrimental in patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is unclear </plain></SENT>
<SENT sid="3" pm="."><plain>We reviewed clinical outcomes in 2 patients who had IVC filter placement years before the diagnosis of the APS and 1 who had a contraindication to anticoagulation </plain></SENT>
<SENT sid="4" pm="."><plain>Recurrent <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e> were seen despite the presence of the filter </plain></SENT>
<SENT sid="5" pm="."><plain>IVC pathology sometimes revealed <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> both proximal and distal to the IVC filter </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">Pulmonary emboli</z:e> in the APS may be secondary to <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> (DVT) </plain></SENT>
<SENT sid="7" pm="."><plain>They may also occur secondary to a cardiac source or in situ <z:mp ids='MP_0005048'>thrombosis</z:mp> in the pulmonary vessels </plain></SENT>
<SENT sid="8" pm="."><plain>An IVC filter will not be of benefit if the heart or the lungs are the primary source for the emboli </plain></SENT>
<SENT sid="9" pm="."><plain>It may also not protect against propagation of a more distal <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> if collateral vessels develop around the filter or a <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> is present on the proximal side of the filter </plain></SENT>
<SENT sid="10" pm="."><plain>Recurrence of <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e> after a filter placement should alert the clinician to the possibility of a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> such as APS </plain></SENT>
<SENT sid="11" pm="."><plain>Clinicians need to assess risks and benefits carefully before placing a permanent IVC filter in patients with APS </plain></SENT>
<SENT sid="12" pm="."><plain>Whether a temporary or retrievable filter is safer in APS and more effective is unknown at the present time </plain></SENT>
</text></document>